3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
34
Neoplasms
8
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
HER2-positive Breast Cancer
3
Salivary Gland Neoplasms
2
Pathologic Complete Response
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
HER2-positive Early Breast Cancer
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
Liver Neoplasms
1
Hemangiosarcoma
1
Heart Failure
1
Interventions
Blood Specimen Collection
5
Liquid Biopsy
2
Folfox protocol
2
Carboplatin
2
pertuzumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Standard of Care
1
Sevoflurane
1
Radiotherapy, Adjuvant
1
Propofol
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
Neoadjuvant Therapy
1
Mastectomy, Segmental
1
Gemcitabine
1
Fluorouracil
1
Epirubicin
1
Drug Therapy
1
Docetaxel
1
Cyclophosphamide
1
Colonography, Computed Tomographic
1
Cisplatin
1
Chemotherapy, Adjuvant
1
Capecitabine
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplastic Cells, Circulating
×
pertuzumab
×
Clear all
NCT04993014
2021-08-06
HER2Cell
AC Camargo Cancer Center
Phase 2
Recruiting
80 enrolled